ArticleCureus2025
A Prospective Study of the Role of Tranexamic Acid in Postoperative Bleeding and Seroma in Modified Radical Mastectomy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy of Aminocaproic Acid in Preventing Postoperative Hematoma in Breast Cancer Surgery: A Prospective Study.Journal of surgical oncology · 2026Trial
- Comparative Effects of Thymoquinone, Tranexamic Acid, and Porcine Dermal Collagen on Seroma Formation and Tissue Remodeling After Mastectomy in a Rat Model.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundModified radical mastectomy (MRM) is a common surgical procedure for breast cancer, but is frequently complicated by seroma formation and postoperative bleeding, leading to morbidity and delayed recovery. Tranexamic acid (TXA), an antifibrinolytic agent, has shown efficacy in reducing blood loss across surgical specialties. This study evaluates its role in minimizing postoperative bleeding and seroma formation following MRM.
methodsA non-randomized interventional study was conducted at the Department of General Surgery, All India Institute of Medical Sciences (AIIMS), Bhopal, from April 2023 to August 2024. Fifty female breast cancer patients undergoing MRM were enrolled and allocated to two groups: TXA group (n=25) and non-TXA group (NTXA, n=25). The TXA group received 1 g IV TXA at anesthesia induction, followed by 500 mg orally every eight hours for five days. Demographic variables, comorbidities, intraoperative blood loss, and postoperative parameters (daily and total drain output, drain duration, seroma formation, wound healing, and hospital stay) were recorded. Data were analyzed using IBM SPSS Statistics, version 25 (IBM Corp., Armonk, USA), with p < 0.05 considered significant.
resultsBoth groups were comparable with reference to age, BMI, and clinical stage. Mean intraoperative blood loss was significantly lower in the TXA group (84.8 ± 32.06 ml) compared to the NTXA group (106.4 ± 37.95 ml; p = 0.04). Although total drain output (p = 0.33) and drain duration (p = 0.36) were not significantly different, daily drain output was significantly lower in the TXA group from Day 4 onwards (Day 4, p = 0.03; Day 5, p = 0.04; Day 6, p = 0.02; Day 7, p = 0.02). Seroma formation after drain removal occurred in 3 (12%) of TXA patients versus 5 (20%) in the NTXA group, but this was not statistically significant (p = 0.70). The mean hospital stay was significantly shorter in the TXA group (6.13 ± 2.29 days) than in the NTXA group (7.40 ± 1.84 days; p < 0.01).
conclusionTranexamic acid significantly reduces intraoperative blood loss and late postoperative drain output in MRM patients. However, it does not significantly decrease overall seroma incidence or drain duration. Importantly, TXA use was associated with a shorter hospital stay. Larger randomized controlled trials are warranted to validate its role in reducing postoperative complications following MRM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.